Gilead and Galapagos close in on filing for Xeljanz rival - PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival  PMLiVE

Galapagos and Gilead Sciences have a pair of positive phase 3 trials for their JAK inhibitor filgotinib in rheumatoid arthritis that they say make it a contender in ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases